药物涂层球囊治疗冠状动脉原位病变的有效性及安全性

程辉; 彭杰成; 伍万仕; 江庆

doi:10.12025/j.issn.1008-6358.2023.20231366

药物涂层球囊治疗冠状动脉原位病变的有效性及安全性

Efficacy and safety of drug-coated balloon in the treatment of de novo coronary artery disease

摘要

摘要:
目的探讨药物涂层球囊(drug-coated balloon，DCB)治疗冠状动脉原位病变的安全性和有效性。
方法回顾性选择2021年2月至2022年6月在安徽医科大学附属安庆第一人民医院进行介入治疗的85例冠状动脉原位病变患者，根据介入治疗方法分为药物洗脱支架(drug-eluting stent，DES)组(n=45)和DCB组(n=40)。比较两组患者术前、术后即刻和术后6个月的最小管腔直径(minimal lumen diameter，MLD)和管腔狭窄程度，手术即刻成功率，术中并发症发生率，术后6个月的晚期管腔丢失(late lumen loss，LLL)，术后6个月内主要不良心血管事件(major adverse cardiovascular event，MACE)发生率。
结果 DCB组术后即刻与术后6个月MLD小于DES组(P < 0.001)；DCB组术后即刻管腔狭窄程度大于DES组(P < 0.001)，术后6个月与DES组差异无统计学意义。DCB组手术即刻成功率为95.00%，与DES组(97.78%)差异无统计学意义。两组患者术中并发症发生率差异无统计学意义。DCB组术后6个月LLL、MACE发生率均低于DES组(P < 0.05)。
结论 DCB治疗冠状动脉原位病变的即刻成功率较高，可明显改善动脉血管狭窄情况，且安全性较高。

Abstract:
Objective To explore the safety and efficacy of drug-coated balloon (DCB) in the treatment of de novo coronary artery disease.
Methods A total of 85 patients with de novo coronary artery disease undergoing interventional therapy in Anqing First People's Hospital Affiliated to Anhui Medical University from February 2021 to June 2022 were retrospectively included, and were divided into drug-eluting stent (DES) group (n=45) and DCB group (n=40) according to different interventional therapies. The minimal lumen diameter (MLD) and the degree of lumen stenosis before surgery, immediately after surgery and at 6 months after surgery, immediate success rate of surgery and incidence of intraoperative complications, late lumen loss (LLL) at 6 months after surgery, incidence of major adverse cardiovascular event (MACE) within 6 months after surgery were compared between the two groups.
Results Immediately and at 6 months after surgery, MLD in DCB group was significantly shorter than that in DES group (P < 0.001). Immediately after surgery, lumen stenosis in DCB group was significantly severer than that in DES group (P < 0.001), but there was no significant difference between the two groups at 6 months after surgery. There was no significant difference in immediate success rate of surgery between DCB group and DES group (95.00% vs 97.78%). There was no significant difference in incidence of intraoperative complications between the two groups. At 6 months after surgery, incidences of LLL and MACE in DCB group were significantly lower than those in DES group (P < 0.05).
Conclusions DCB interventional therapy has high immediate success rate of surgery for de novo coronary artery disease, which can significantly improve arterial vascular stenosis, with good safety.

HTML全文

参考文献(17)

施引文献

资源附件(0)